These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36700320)

  • 21. Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression.
    Shao S; Sun B; Sun H
    Pak J Med Sci; 2022; 38(5):1389-1394. PubMed ID: 35799757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
    Liebowitz MR; Yeung PP; Entsuah R
    J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder.
    Santi NS; Biswal SB; Naik BN; Sahoo JP; Rath B
    Cureus; 2023 Apr; 15(4):e37858. PubMed ID: 37213947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study.
    Lee SH; Jeon SW; Shin C; Pae CU; Patkar AA; Masand PS; An H; Han C
    Psychiatry Investig; 2022 Jun; 19(6):500. PubMed ID: 35753689
    [No Abstract]   [Full Text] [Related]  

  • 25. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
    Farabaugh AH; Bitran S; Witte J; Alpert J; Chuzi S; Clain AJ; Baer L; Fava M; McGrath PJ; Dording C; Mischoulon D; Papakostas GI
    Int Clin Psychopharmacol; 2010 Jul; 25(4):214-7. PubMed ID: 20400905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcutaneous Electrical Cranial-Auricular Acupoint Stimulation vs. Escitalopram for Patients With Mild-to-Moderate Depression (TECAS): Study Design for a Randomized Controlled, Non-inferiority Trial.
    Yang S; Qin Z; Yang X; Chan MY; Zhang S; Rong P; Hou X; Jin G; Xu F; Liu Y; Zhang ZJ
    Front Psychiatry; 2022; 13():829932. PubMed ID: 35619617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
    Dolder C; Nelson M; Stump A
    Drugs Aging; 2010 Aug; 27(8):625-40. PubMed ID: 20658791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report.
    Khoo Y; Demchenko I; Frey BN; Milev RV; Ravindran AV; Parikh SV; Ho K; Rotzinger S; Lou W; Lam RW; Kennedy SH; Bhat V;
    J Affect Disord; 2022 Mar; 300():50-58. PubMed ID: 34921820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.
    Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV
    Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram.
    Papakostas GI; Larsen K
    Eur Arch Psychiatry Clin Neurosci; 2011 Apr; 261(3):147-56. PubMed ID: 20859636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of escitalopram in treatment of severe depression in Chinese population.
    Si T; Wang G; Yang F; Fang Y; Fang M; Li J; Dong J; Shen X; Zhuo J; Rui Q; Wang J; Cuili H
    Metab Brain Dis; 2017 Jun; 32(3):891-901. PubMed ID: 28299626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
    Davidson JR; Bose A; Korotzer A; Zheng H
    Depress Anxiety; 2004; 19(4):234-40. PubMed ID: 15274172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized Controlled Trial Comparing the Quality of Life and Medication Adherence in Patients on Antidepressant Monotherapy.
    Santi NS; Biswal SB; Naik BN; Sahoo JP; Rath B
    Cureus; 2024 Jun; 16(6):e62418. PubMed ID: 39011217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatr Res; 2015 May; 64():88-98. PubMed ID: 25851751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
    Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.